Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Stigma as a Barrier to HBV Care: Patient and Physician Sharing Session #2

In episode 2 of this ongoing series, listen to a conversation between Robert G. Gish, MD, FAASLD, and patient and advocate, Alan Wang, on approaches to destigmatize HBV infection and remove barriers to care.
Robert G. Gish, MD
Released: April 12, 2021

In episode 2 of an ongoing series of sharing sessions between a physician and patient, Robert Gish, MD, FAASLD, and patient advocate, Alan Wang, discuss stigma as a barrier to optimal HBV care and treatment. The conversation focuses on how stigma affected Alan’s engagement with his care and strategies to overcome stigma as a barrier to HBV care.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from:
Gilead Sciences, Inc.

Information on this Educational Activity

Faculty

Robert G. Gish, MD

Professor of Medicine
Loma Linda University
Loma Linda, California
Medical Director
Hepatitis B Foundation
Washington, DC

Robert G. Gish, MD, has disclosed that he has received funds for research support from Gilead Sciences; has received consulting fees from Abbott, AbbVie, Access Biologicals, Antios, Arrowhead, Bayer AG, Bristol-Myers Squibb, Dova, Dynavax, Eiger, Eisai, Enyo, eStudySite, Forty-Seven, Genentech, Genlantis, Gilead Sciences, Hepatx, HepQuant, Intercept, Janssen, Helios, Lilly, Merck, Salix, Shionogi, and Viking; has served on advisory boards for Abbott, AbbVie, Antios, Arrowhead, Bayer, BioCollections, Dova, Eiger, Enyo, Fibronostics, Fujifilm/Wako, Gilead Sciences, HepQuant, Intercept, Janssen, Merck, Prodigy, and Topography Health; and has served on data and safety monitoring boards for Altimmune, Arrowhead, and CymaBay.

Program Medium

This program has been made available online.

Related Content

Brief Clinical Care Options (CCO) presentation on APASL guidance on limitations of current HCC surveillance recommendations in chronic HBV infection

George Lau, MBBS (HKU), MD (HKU), FRCP (Edin, Lond), FAASLD (USA) Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: October 7, 2021 Expired: October 6, 2022

Takeshi Saito, MD, PhD, discusses the limitations of current approaches to treating HDV and looks ahead to new and emerging HDV therapies, from Clinical Care Options (CCO)

Takeshi Saito, MD, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 28, 2021 Expired: September 27, 2022

Download key slides describing lessons learned in delivery of care from the COVID-19 pandemic worth carrying forward in the management of viral hepatitis.

Gregory Dore, MBBS, PhD, FRACP, MPH Stacey Trooskin, MD, PhD, MPH Released: September 23, 2021

Brief Clinical Care Options (CCO) presentation on using the EASL guidelines to determine treatment candidacy in patients with hepatitis B virus HBV.

Maria Buti, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 7, 2021 Expired: September 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue